Application of Cephalaine hydrochloride in preparation of medicine for resisting influenza A virus infection

By extracting Cephaeline hydrochloride from plants as an anti-influenza A virus infection drug, the problem of insufficient safety and effectiveness of drugs in the existing technology has been solved, and the efficient and safe influenza A virus inhibition effect has been achieved, which has been a global influenza epidemic. New treatment options are provided.

CN118948851APending Publication Date: 2024-11-15SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411055985.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art lacks effective drugs to inhibit influenza A virus, and traditional chemical synthetic drugs may have side effects, resulting in insufficient safety and effectiveness.

Method used

Using the natural chemical ingredient Cephaeline hydrochloride, it is prepared into a variety of dosage forms by extracting and applying it from plants to anti-influenza A virus infection drugs combined with pharmaceutically acceptable carriers to improve efficacy and safety.

Benefits of technology

Cephaeline hydrochloride shows strong anti-influenza A virus inhibitory power, low IC50 value, low cytotoxicity, high selection index, and provides a safe and effective treatment plan suitable for the treatment of respiratory infections and encephalitis and other diseases. The global flu epidemic provides new treatment methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948851A_ABST
    Figure CN118948851A_ABST
Patent Text Reader

Abstract

The invention provides an application of Cephalaine hydrochloride in preparation of a medicament for resisting influenza A virus infection, and belongs to the technical field of biological medicines. According to the present invention, the small molecule Cephalaine hydrochloride has strong inhibition effect on influenza A virus, IC50 is equal to 0.012 [mu] M, the value is low, and the inhibition efficiency is high; the invention also detects the toxicity condition of the Cephalaine hydrochloride to cells, and finds that the Cephalaine hydrochloride has low toxicity to cells, high CC50 and a selection index (SI) far higher than a safety range, so that the safety and effectiveness of the Cephalaine hydrochloride as an IAV influenza A virus inhibitor are better guaranteed, and the Cephalaine hydrochloride can be used for treating respiratory system infection, pneumonia, encephalitis and other diseases caused by the influenza A virus, and has good application prospects. And a novel effective treatment medicine is provided for the global influenza epidemic situation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to application of Cephaeline hydrochloride in preparing drugs for resisting influenza A virus infection. Background Art

[0002] Influenza A virus (IAV) is a human respiratory pathogen that is widely prevalent around the world. It is highly contagious and pathogenic, and can cause severe respiratory infections, pneumonia, encephalitis and other diseases, and even worse, can lead to death. Influenza A virus belongs to the Orthomyxoviridae family and is an enveloped negative-strand RNA virus. It can be divided into several subtypes, such as H1N1, H3N2, etc., based on the different antigenic properties of the hemagglutinin protein (HA) and neuraminidase protein (NA) on its surface.

[0003] IAV is also a zoonotic pathogen with multiple hosts. It can be transmitted between species and reclassified into different virus types, which in turn leads to the emergence and widespread spread of new influenza virus epidemics. Among them, the Spanish flu outbreak between 1918 and 1919 was the most serious, causing more than 40 million deaths. Currently, there are few specific drugs for the treatment of influenza A virus, so drugs that have an inhibitory effect on influenza A virus have always been the focus of researchers.

[0004] The method of using natural chemical components extracted from typical Chinese medicine to inhibit IAV has strong medical value and clinical potential, and is in line with the general research direction of combining Chinese and Western medicine. Compared with the artificially synthesized small molecules of medicinal chemistry previously used to inhibit IAV, the natural chemical molecules extracted from plant components can more effectively avoid the possible side effects of chemical synthetic molecules on humans, and are more secure in terms of safety and social promotion.

[0005] Ipecac was commonly used as an emetic in the early days, and also has the effects of treating cough, bronchitis, whooping cough, hepatitis, fever, morning sickness, gynecological diseases, amoebic dysentery, loss of appetite, cancer, etc. The natural Chinese medicine small molecule compound Cephaeline hydrochloride is a type of phenolic alkaloid separated from ipecac, and is one of the important natural active ingredients. This small molecule is mainly used for anti-cancer treatment. It is a mature drug small molecule and is derived from natural plant ingredients. Therefore, it has the safety premise of becoming a good inhibitor of influenza A virus.

[0006] Currently, there are few reports on the antiviral effect of the small molecule compound Cephaeline hydrochloride. Therefore, further developing the antiviral effect of Cephaeline hydrochloride is of great significance to solving the global influenza epidemic. Summary of the invention

[0007] The purpose of the present invention is to provide an application of Cephaeline hydrochloride in the preparation of a drug for resisting influenza A virus infection. Cephaeline hydrochloride is used for resisting influenza A virus infection, and has good inhibitory effect and high safety.

[0008] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0009] The invention provides application of Cephaeline hydrochloride in preparing drugs for resisting influenza A virus infection.

[0010] Furthermore, the structure of Cephaeline hydrochloride is shown in formula (I):

[0011]

[0012] Furthermore, the Cephaeline hydrochloride can inhibit the infection and replication of influenza A virus.

[0013] Furthermore, the anti-influenza A virus infection drug may be added with a pharmaceutically acceptable carrier.

[0014] Furthermore, the dosage form of the anti-influenza A virus infection drug is one of powder, solution, capsule, granule, tablet, emulsion and suspension.

[0015] The application of Cephaeline hydrochloride in the present invention in the preparation of anti-influenza A virus infection drugs has the following beneficial effects compared with the prior art:

[0016] (1) The present invention uses a small molecule Cephaeline hydrochloride to inhibit influenza A virus, and detects the IC of the inhibitory effect of Cephaeline hydrochloride 50 The results showed that Cephaeline hydrochloride has a strong inhibitory effect on influenza A virus, IC 50=0.012μM, which is a low value and has a high inhibition efficiency. The toxicity of small molecule Cephaeline hydrochloride to cells was also tested and found that its toxicity to cells was also low, CC 50 =112.9 μM, which is a relatively high value, and the selectivity index (SI) is much higher than the safe range, which provides better assurance for the safety and effectiveness of Cephaeline hydrochloride as an IAV influenza A virus inhibitor.

[0017] (2) The present invention utilizes a natural chemical component extracted from plants - a small molecule Cephaeline hydrochloride to inhibit influenza A virus, which can effectively avoid the side effects of chemically synthesized molecules and has high safety. In addition, the small molecule Cephaeline hydrochloride has a high inhibition efficiency on influenza A virus. It can be used to treat respiratory infections, pneumonia, encephalitis and other diseases caused by influenza A virus, providing a new effective therapeutic drug for the global influenza epidemic. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0019] Figure 1 The cytotoxicity curve of Cephaeline hydrochloride and the inhibition rate curve of IAV in Experimental Example 1 are shown. DETAILED DESCRIPTION

[0020] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0021] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0022] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0023] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.

[0024] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0025] The manufacturer of the small molecule Cephaeline hydrochloride used in the following examples of the present invention is targetmo, with product number T3S1852 CAS 3738-70-3.

[0026] Cephaeline hydrochloride of the present invention belongs to terpenoid compounds, and its molecular formula is: 28 H 39 ClN2O4, molecular weight: 503.07, solubility: DMSO: 50 mg / mL (99.39 mM), structure see formula (I):

[0027]

[0028] Example 1

[0029] Example 1 of the present invention screens drugs for inhibiting influenza A virus, specifically comprising the following steps:

[0030] Preliminary screening of small molecules with IAV inhibitory activity in the drug small molecule library:

[0031] The concentration of drug small molecules in the small molecule library is 10mM (in DMSO). The screened IAV is connected to a gene expressing Gaussia Luciferase (Gluc) luciferase. The infection and replication of the virus in the host cells can be obtained by detecting the value of luciferin after infecting the cells.

[0032] Cephaeline hydrochloride, a small molecule in the small molecule library, was diluted 1000 times to 10 μM in Mock DMEM, and then the IAVA / PR / 8 / 34 (PR8)-Gluc strain was added to it. The titer of the original venom was 1.0×10 5 The final venom concentration was diluted 100 times and mixed with MDCK cells for 24 hours before the cells were tested for fluorescence (Gaussia-Lumi TM Gaussia luciferase reporter gene detection kit (Biyuntian Biotechnology), and added positive control group and negative control group of IAV virus-infected and virus-free pure cells for luciferin detection. Finally, it was found that the luciferin value of Cephaeline hydrochloride was close to the luciferin detection value of the pure cell control group, while the luciferin detection values ​​of most other small molecules were close to the luciferin value of the control group of IAV-infected cells only. It can be seen that Cephaeline hydrochloride has an inhibition rate of nearly 100% on IAV and can be used to prepare drugs for the treatment of influenza A virus infection.

[0033] Example 2

[0034] In Example 2 of the present invention, a tablet-type influenza A virus infection-resistant drug is prepared using Cephaeline hydrochloride, and the specific preparation method is as follows:

[0035] Take Cephaeline hydrochloride, add conventional excipients for preparing tablets, mix well, and perform tableting.

[0036] Example 3

[0037] In Example 3 of the present invention, Cephaeline hydrochloride is used to prepare an anti-influenza A virus infection drug in the form of an granule, and the specific preparation method is as follows:

[0038] Take Cephaeline hydrochloride, add the conventional excipients for preparing granules, mix well, and package.

[0039] Example 4

[0040] In Example 4 of the present invention, Cephaeline hydrochloride is used to prepare an aerosol anti-influenza A virus infection drug, and the specific preparation method is as follows:

[0041] Take Cephaeline hydrochloride, add conventional excipients for preparing aerosols such as propellants and various additives for filling.

[0042] Example 5

[0043] In Example 5 of the present invention, Cephaeline hydrochloride is used to prepare a capsule-based drug for preventing influenza A virus infection. The specific preparation method is as follows:

[0044] Take Cephaeline hydrochloride, add the conventional excipients for preparing capsules, mix well, quantitatively fill into a capsule shell made of gelatin as the main material and seal it.

[0045] Test Example 1

[0046] Test Example 1 of the present invention detected the inhibitory effect of Cephaeline hydrochloride on IAV and its cytotoxicity, and the specific method was as follows:

[0047] (1) Inhibition effect detection:

[0048] The small molecule Cephaeline hydrochloride was diluted in Mock DMEM to concentrations of 50μM, 25μM, 10μM, 5μM, 2.5μM, 1μM, 0.1μM, 0.01μM, and 0.001μM. Different concentrations of Cephaeline hydrochloride were used to treat MDCK cells. At the same time, the MDCK cells were infected with IAV-Gluc. Luciferase detection was performed and the value was read 24 hours after infection. The curve analysis of the results was then performed to finally obtain the small molecule concentration value IC that achieved half the inhibition rate. 50 , the results are shown in Figure 1 .

[0049] (2) Cytotoxicity assay:

[0050] The small molecule Cephaeline hydrochloride was diluted in Mock DMEM to concentrations of 1000μM, 500μM, 250μM, 166.67μM, 100μM, 50μM, 25μM, 10μM, 5μM, 2.5μM, 1μM, 0.33μM, 0.1μM, and 0.01μM. Cells were incubated with different concentrations of the small molecule Cephaeline hydrochloride, and five groups of cells under the same conditions were set up for average control. The cytotoxicity was measured by the CCK8 kit (Enhanced Cell Counting Kit-8 Biyuntian Biotechnology), and the cytotoxicity curve of the small molecule was drawn. The curve analysis of the results was then performed to finally obtain the small molecule concentration value CC at which the cytotoxicity reached half. 50 , the results are as follows Figure 1 shown.

[0051] Depend on Figure 1It can be seen that Cephaeline hydrochloride has a strong inhibitory effect on influenza A virus, IC 50= 0.012μM, a low value. 50 =112.9 μM, which is a relatively high value, has a relatively low toxicity to cells, and the selectivity index (SI) is much higher than the safe range, which provides greater assurance for the safety and effectiveness of Cephaeline hydrochloride as an IAV influenza A virus inhibitor.

[0052] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of Cephaeline hydrochloride in the preparation of drugs for anti-influenza A virus infection.

2. The use of Cephaeline hydrochloride in the preparation of anti-influenza A virus infection drugs according to claim 1, characterized in that: The structure of the Cephaeline hydrochloride is shown in formula (I):

3. The use of Cephaeline hydrochloride in the preparation of anti-influenza A virus infection drugs according to claim 2, characterized in that: The Cephaeline hydrochloride can inhibit the infection and replication of influenza A virus.

4. The use of Cephaeline hydrochloride in the preparation of anti-influenza A virus infection drugs according to claim 3, characterized in that: The anti-influenza A virus infection drug may be added with a pharmaceutically acceptable carrier.

5. The use of Cephaeline hydrochloride in the preparation of anti-influenza A virus infection drugs according to claim 4, characterized in that: The dosage form of the anti-influenza A virus infection drug is one of powder, solution, capsule, granule, tablet, emulsion and suspension.